|
1
|
Rajkumar SV: Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 95:548–567. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nobili L, Ronchetti D, Agnelli L, Taiana E, Vinci C and Neri A: Long non-coding RNAs in multiple myeloma. Genes (Basel). 9:692018. View Article : Google Scholar
|
|
3
|
Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma. Nat Rev Dis Primers. 3:170462017. View Article : Google Scholar
|
|
4
|
Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abdulle AS, et al Global Burden of Disease Cancer Collaboration: Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 5:1749–1768. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M and Dimopoulos MA: Pathogenesis of bone disease in multiple myeloma: From bench to bedside. Blood Cancer J. 8:72018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X and Anderson KC: Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond. Leukemia. 32:252–262. 2018. View Article : Google Scholar :
|
|
7
|
Soekojo CY, Ooi M, de Mel S and Chng WJ: Immunotherapy in multiple myeloma. Cells. 9:92020. View Article : Google Scholar
|
|
8
|
Robak P, Drozdz I, Szemraj J and Robak T: Drug resistance in multiple myeloma. Cancer Treat Rev. 70:199–208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio ME, Romeo E, et al: Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 32:1948–1957. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H, Yang H and Sun J: Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res. 34:1022015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kopp F and Mendell JT: Functional classification and experi- mental dissection of long noncoding RNAs. Cell. 172:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen Y, Feng Y, Chen H, Huang L, Wang F, Bai J, Yang Y, Wang J, Zhao W, Jia Y, et al: Focusing on long non-coding RNA dysregulation in newly diagnosed multiple myeloma. Life Sci. 196:133–142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, et al: The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood. 124:1765–1776. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, et al: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17:e328–e346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, et al Mayo Clinic: Management of newly diagnosed symptomatic multiple myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 88:360–376. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grammatikakis I, Zhang P, Panda AC, Kim J, Maudsley S, Abdelmohsen K, Yang X, Martindale JL, Motiño O, Hutchison ER, et al: Alternative splicing of neuronal differentiation factor TRF2 regulated by HNRNPH1/H2. Cell Rep. 15:926–934. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peng Y, Li F, Zhang P, Wang X, Shen Y, Feng Y, Jia Y, Zhang R, Hu J and He A: IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition. Life Sci. 249:1175032020. View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
20
|
Schmitz SU, Grote P and Herrmann BG: Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 73:2491–2509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cho SF, Chang YC, Chang CS, Lin SF, Liu YC, Hsiao HH, Chang JG and Liu TC: MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer. 14:8092014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Handa H, Kuroda Y, Kimura K, Masuda Y, Hattori H, Alkebsi L, Matsumoto M, Kasamatsu T, Kobayashi N, Tahara KI, et al: Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. Br J Haematol. 179:449–460. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu Y, Lin J, Fang H, Fang J, Li C, Chen W, Liu S, Ondrejka S, Gong Z, Reu F, et al: Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 32:2250–2262. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li B, Chen P, Qu J, Shi L and Zhuang W, Fu J, Li J, Zhang X, Sun Y and Zhuang W: Activation of LTBP3 gene by a long noncoding RNA (lncRNA) MALAT1 transcript in mesenchymal stem cells from multiple myeloma. J Biol Chem. 289:29365–29375. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu H, Wang H, Wu B, Yao K, Liao A, Miao M, Li Y and Yang W: Down-regulation of long non-coding RNA MALAT1 by RNA interference inhibits proliferation and induces apoptosis in multiple myeloma. Clin Exp Pharmacol Physiol. 44:1032–1041. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sedlarikova L, Gromesova B, Kubaczkova V, Radova L, Filipova J, Jarkovsky J, Brozova L, Velichova R, Almasi M, Penka M, et al: Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. Eur J Haematol. 99:223–33. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu Y and Wang H: LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol. 32:e220082018. View Article : Google Scholar
|
|
28
|
Hu J, Shan Y, Ma J, Pan Y, Zhou H, Jiang L and Jia L: LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α-2,3 sialylation via PI3K/Akt signaling. Int J Cancer. 145:450–460. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gan L, Lv L and Liao S: Long non coding RNA H19 regulates cell growth and metastasis via the miR 22 3p/Snail1 axis in gastric cancer. Int J Oncol. 54:2157–2168. 2019.PubMed/NCBI
|
|
30
|
Luo M, Li Z, Wang W, Zeng Y, Liu Z and Qiu J: Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression. Cancer Lett. 333:213–221. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen SW, Zhu J, Ma J, Zhang JL, Zuo S, Chen GW, Wang X, Pan YS, Liu YC and Wang PY: Overexpression of long non-coding RNA H19 is associated with unfavorable prognosis in patients with colorectal cancer and increased proliferation and migration in colon cancer cells. Oncol Lett. 14:2446–2452. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng R, Wang Y, Huang J, Xu M, Yan J, et al: lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. FEBS J. 281:3766–3775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ding K, Liao Y, Gong D, Zhao X and Ji W: Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma. Biochem Biophys Res Commun. 502:194–201. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tsang WP and Kwok TT: Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 26:4877–4881. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Teppa RE, Petit D, Plechakova O, Cogez V and Harduin-Lepers A: Phylogenetic-derived insights into the evolution of sialylation in eukaryotes: Comprehensive analysis of vertebrate β-galactoside α2,3/6-sialyltransferases (ST3Gal and ST6Gal). Int J Mol Sci. 17:172016. View Article : Google Scholar
|
|
36
|
Sun M, Zhao X, Liang L, Pan X, Lv H and Zhao Y: Sialyltransferase ST3GAL6 mediates the effect of microRNA-26a on cell growth, migration, and invasion in hepatocellular carcinoma through the protein kinase B/mammalian target of rapamycin pathway. Cancer Sci. 108:267–276. 2017. View Article : Google Scholar :
|
|
37
|
Shi J, Li YM and Fang XD: The mechanism and clinical significance of long noncoding RNA-mediated gene expression via nuclear architecture. Yi Chuan. 39:189–199. 2017.PubMed/NCBI
|
|
38
|
Jandura A and Krause HM: The new RNA world: Growing evidence for long noncoding RNA functionality. Trends Genet. 33:665–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alvarez-Dominguez JR and Lodish HF: Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood. 130:1965–1975. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Geuens T, Bouhy D and Timmerman V: The hnRNP family: Insights into their role in health and disease. Hum Genet. 135:851–867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ford LP, Wright WE and Shay JW: A model for heterogeneous nuclear ribonucleoproteins in telomere and telomerase regulation. Oncogene. 21:580–583. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shishkin SS, Kovalev LI, Pashintseva NV, Kovaleva MA and Lisitskaya K: Heterogeneous nuclear ribonucleoproteins involved in the functioning of telomeres in malignant cells. Int J Mol Sci. 20:202019. View Article : Google Scholar
|
|
43
|
He Y and Smith R: Nuclear functions of heterogeneous nuclear ribonucleoproteins A/B. Cell Mol Life Sci. 66:1239–1256. 2009. View Article : Google Scholar
|
|
44
|
Wang L, Wen M and Cao X: Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses. Science. 365:3652019. View Article : Google Scholar
|
|
45
|
Qin G, Tu X, Li H, Cao P, Chen X, Song J, Han H, Li Y, Guo B, Yang L, et al: Long Noncoding RNA p53-stabilizing and activating RNA promotes p53 signaling by inhibiting heterogeneous nuclear ribonucleoprotein K deSUMOylation and suppresses hepatocellular carcinoma. Hepatology. 71:112–129. 2020. View Article : Google Scholar
|
|
46
|
Lan X, Yan J, Ren J, Zhong B, Li J, Yue L, Liu L, Yi J, Sun Q, Yang X, et al: A novel long noncoding RNA Lnc-HC binds hnRNPA2B1 to regulate expressions of Cyp7a1 and Abca1 in hepatocytic cholesterol metabolism. Hepatology. 64:58–72. 2016. View Article : Google Scholar
|
|
47
|
Chen C, Luo Y, He W, Zhao Y, Kong Y, Liu H, Zhong G, Li Y, Li J, Huang J, et al: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J Clin Invest. 130:404–421. 2019. View Article : Google Scholar : PubMed/NCBI
|
